2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 757

Impact Of Cardiac Magnetic Resonance Imaging On Eosinophilic Granulomatosis With Polyangiitis Outcomes: A Long-Term Retrospective Study On 42 Patients
Abstract Number: 2392

Impact Of CT-P13 and Originator Infliximab Treatment On Quality Of Life Derived From The Health Assessment Questionnaire (HAQ) and Short-Form 36 (SF-36) From a Randomized, Double-Blind Trial In Patients With Active RA
Abstract Number: 2880

Impact Of Different End Points On The Patient Cohort Size Needed To Demonstrate The Efficacy Of a Therapeutic Intervention In Pss. A Post Hoc Analysis Of The Tears Study (Tolerance and efficacy of Rituximab in primary Sjogren Syndrome study)
Abstract Number: 1267

Impact Of Disease Duration On Vascular Surrogates Of Early Atherosclerosis In Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 1984

Impact Of Educational Attainment On Health-Related Quality Of Life and Healthcare Utilization Among Veterans With Gout
Abstract Number: 2359

Impact Of Etanercept-Methotrexate Treatment Withdrawal On Patient-Reported Outcomes In Patients With Early Rheumatoid Arthritis (PRIZE Trial)
Abstract Number: 2311

Impact Of Healing Architecture In a Rheumatology Outpatient Clinic
Abstract Number: 453

Impact Of Inadequate Adherence On Clinical Outcomes: Results From The Biologics In Rheumatoid Arthritis Genetics and Genomics Study Syndicate Cohort
Abstract Number: 314

Impact Of Low Infliximab Dose Regimen On Treatment Response and Drug Survival In 462 Patients With Psoriatic Arthritis. Results From The Nationwide Registries Danbio and Icebio
Abstract Number: 675

Impact Of Male Sex On Survival In Systemic Sclerosis
Abstract Number: 2686

Impact of Methotrexate Dose Reduction Upon Initiation of Adalimumab On Clinical and Ultrasonographic Parameters in Patients With Moderate to Severe Rheumatoid Arthritis
Abstract Number: 2538

Impact Of Omega-3 Fatty Acids On Quality Of Life In Systemic Lupus Erythematosus
Abstract Number: 341

Impact Of Persistent Minimal Disease Activity On Long-Term Outcomes In Psoriatic Arthritis: Results From 5 Years Of The Long Term Extension Of a Randomized, Placebo-Controlled, Study
Abstract Number: 2317

Impact of PVA Coated Nanoparticles On Cellular Viability and Functionality of Immune Cells Obtained From Healthy Donors and Patients With Rheumatoid Arthritis Or Osteoarthritis
Abstract Number: 2477

Impact Of Stressful Life Events On Disease Activity In Spondyloarthritis: Results Of The Coenv-2 Prospective Cohort Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].